Login / Signup

Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study.

Brian G FeaganKatsuyoshi MatsuokaGerhard RoglerDavid LaharieSéverine VermeireSilvio DaneseEdward V LoftusIan L P BealesStefan SchreiberHyo Jong KimMargaux FaesAngela de HaasTomasz MasiorChristine RudolphLaurent Peyrin Biroulet
Published in: Alimentary pharmacology & therapeutics (2024)
Filgotinib induced and maintained symptomatic remission and improved HRQoL over 4 years. Safety results showed a proven long-term benefit-risk profile. FIL200-treated CDC achievers had better long-term outcomes than non-achievers.
Keyphrases
  • ulcerative colitis
  • open label
  • clinical trial
  • randomized controlled trial
  • rheumatoid arthritis
  • high glucose
  • diabetic rats
  • radiation therapy
  • cell proliferation
  • phase iii
  • combination therapy